IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI
TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT
OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

a 2023

IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

CASAS, D, J ALCEDO, M LAFUENTE, LÓPEZ, A PÉREZ-AISA et. al.

Basic information

Original name

IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Authors

Edition

31st United European Gastroenterology Week 2023, 2023

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.000 in 2022

Organization unit

Faculty of Medicine

ISSN

Změněno: 18/12/2023 09:13, Mgr. Tereza Miškechová

Abstract

V originále

Aims & Methods: Aims: To assess the usefulness of PB use in improving the safety of eradication therapies used in Europe. Methods: Prospective, multicentre, non-interventional registry (HpEuReg) of the clinical practice of European gastroenterologists. Data were collected in an e-CRD in AEG-REDCap from 2013 to 2021. Information was included from countries with at least 30 cases undergoing eradication therapy and at least 1 with associated PB, with controls being patients without PB. AEs were categorised as mild, moderate and severe. Results were grouped by region. A modified intention-to treat analysis and a logistic regression model, considering age, sex, duration and regimen of eradication treatment, PPI dose and adherence were performed. Results: 36,699 patients were included; 8,233 (22%) treated with PB. Multiple PB formulations were used, including 9 genera and 32 species. In the PB group the rate of overall AEs was higher (25% vs 22%, p<0.0001), but the rate of severe AEs was lower (1.9% vs 1.1%, p<0.0001). The duration of AE’s was shorter in the PB group (6.4 vs 8.2 days, p<0.0001). The logistic regression model was applied to data from the Central European region as it has the highest frequency of PB use and, therefore, the lowest risk of prescription driven by expected AEs. In this model, PB use was associated with a lower incidence of both global and severe AEs. In terms of genus, with Bifidobacterium the incidence of at least one AE and that of severe AEs was lower ( p=0.0019 and p<0.001, respectively), while Lactobacillus only had benefit for the incidence of severe AEs associated with triple therapy ( p=0.0278) and Bacillus showed inconsistent results. Conclusion: The use of PB was associated with a lower incidence of AEs, as well as shorter duration and severity of AEs. The genus Bifidobacterium may be the most useful in the prevention of AEs.

Citovat

CASAS, D, J ALCEDO, M LAFUENTE, LÓPEZ, A PÉREZ-AISA, M PAVONI, SARACINO, B TEPES, L JONAITIS, M CASTRO-FERNÁNDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, I VOYNOVAN, L BUJANDA, A J LUCENDO, N Brglez JURECIC, M DENKOVSKI, PHULL, L RODRIGO, A LANAS, MARTÍNEZ-DOMÍNGUEZ, HUGUET, BORDIN, A GASBARRINI, J KUPCINSKAS, G BABAYEVA, O GRIDNYEV, M LEJA, T ROKKAS, R MARCOS-PINTO, F LERANG, D BOLTIN, V PAPP, A TONKIĆ, SMITH, H SIMSEK, M VENERITO, L BOYANOVA, V MILIVOJEVIC, Lumír KUNOVSKÝ, T MATYSIAK-BUDNIK, W MARLICZ, M DOULBERIS, A CANO-CATALÀ, L HERNÁNDEZ, L MOREIRA, NYSSEN, F MEGRAUD, MORAIN and GISBERT. IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG). In 31st United European Gastroenterology Week 2023. 2023. ISSN 2050-6406.

@proceedings{2351120,
   author = {Casas, D and Alcedo, J and Lafuente, M and López, and PérezandAisa, A and Pavoni, M and Saracino, and Tepes, B and Jonaitis, L and CastroandFernández, M and PabónandCarrasco, M and KecoandHuerga, A and Voynovan, I and Bujanda, L and Lucendo, A J and Jurecic, N Brglez and Denkovski, M and Phull, and Rodrigo, L and Lanas, A and MartínezandDomínguez, and Huguet, and Bordin, and Gasbarrini, A and Kupcinskas, J and Babayeva, G and Gridnyev, O and Leja, M and Rokkas, T and MarcosandPinto, R and Lerang, F and Boltin, D and Papp, V and Tonkić, A and Smith, and Simsek, H and Venerito, M and Boyanova, L and Milivojevic, V and Kunovský, Lumír and MatysiakandBudnik, T and Marlicz, W and Doulberis, M and CanoandCatalà, A and Hernández, L and Moreira, L and Nyssen, and Megraud, F and Morain, and Gisbert, },
   booktitle = {31st United European Gastroenterology Week 2023},
   title = {IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)},
   url = {https://onlinelibrary.wiley.com/toc/20506414/2023/11/S8},
   year = {2023}
}

TY  - CONF
ID  - 2351120
AU  - Casas, D - Alcedo, J - Lafuente, M - López,
AU  - Pérez-Aisa, A - Pavoni, M - Saracino,
AU  - Tepes, B - Jonaitis, L - Castro-Fernández, M - Pabón-Carrasco, M - Keco-Huerga, A - Voynovan, I - Bujanda, L - Lucendo, A J - Jurecic, N Brglez - Denkovski, M - Phull,
AU  - Rodrigo, L - Lanas, A - Martínez-Domínguez,
AU  - Huguet,
AU  - Bordin,
AU  - Gasbarrini, A - Kupcinskas, J - Babayeva, G - Gridnyev, O - Leja, M - Rokkas, T - Marcos-Pinto, R - Lerang, F - Boltin, D - Papp, V - Tonkić, A - Smith,
AU  - Simsek, H - Venerito, M - Boyanova, L - Milivojevic, V - Kunovský, Lumír - Matysiak-Budnik, T - Marlicz, W - Doulberis, M - Cano-Català, A - Hernández, L - Moreira, L - Nyssen,
AU  - Megraud, F - Morain,
AU  - Gisbert,
PY  - 2023
TI  - IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
UR  - https://onlinelibrary.wiley.com/toc/20506414/2023/11/S8
N2  - Aims & Methods: Aims: To assess the usefulness of PB use in improving the safety of eradication therapies used in Europe. Methods: Prospective, multicentre, non-interventional registry (HpEuReg) of the clinical practice of European gastroenterologists. Data were collected in an e-CRD in AEG-REDCap from 2013 to 2021. Information was included from countries with at least 30 cases undergoing eradication therapy and at least 1 with associated PB, with controls being patients without PB. AEs were categorised as mild, moderate and severe. Results were grouped by region. A modified intention-to treat analysis and a logistic regression model, considering age, sex, duration and regimen of eradication treatment, PPI dose and adherence were performed. Results: 36,699 patients were included; 8,233 (22%) treated with PB. Multiple PB formulations were used, including 9 genera and 32 species. In the PB group the rate of overall AEs was higher (25% vs 22%, p<0.0001), but the rate of severe AEs was lower (1.9% vs 1.1%, p<0.0001). The duration of AE’s was shorter in the PB group (6.4 vs 8.2 days, p<0.0001). The logistic regression model was applied to data from the Central European region as it has the highest frequency of PB use and, therefore, the lowest risk of prescription driven by expected AEs. In this model, PB use was associated with a lower incidence of both global and severe AEs. In terms of genus, with Bifidobacterium the incidence of at least one AE and that of severe AEs was lower ( p=0.0019 and p<0.001, respectively), while Lactobacillus only had benefit for the incidence of severe AEs associated with triple therapy ( p=0.0278) and Bacillus showed inconsistent results. Conclusion: The use of PB was associated with a lower incidence of AEs, as well as shorter duration and severity of AEs. The genus Bifidobacterium may be the most useful in the prevention of AEs.
ER  -

CASAS, D, J ALCEDO, M LAFUENTE, LÓPEZ, A PÉREZ-AISA, M PAVONI, SARACINO, B TEPES, L JONAITIS, M CASTRO-FERNÁNDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, I VOYNOVAN, L BUJANDA, A J LUCENDO, N Brglez JURECIC, M DENKOVSKI, PHULL, L RODRIGO, A LANAS, MARTÍNEZ-DOMÍNGUEZ, HUGUET, BORDIN, A GASBARRINI, J KUPCINSKAS, G BABAYEVA, O GRIDNYEV, M LEJA, T ROKKAS, R MARCOS-PINTO, F LERANG, D BOLTIN, V PAPP, A TONKI$\backslash$'C, SMITH, H SIMSEK, M VENERITO, L BOYANOVA, V MILIVOJEVIC, Lumír KUNOVSKÝ, T MATYSIAK-BUDNIK, W MARLICZ, M DOULBERIS, A CANO-CATALÀ, L HERNÁNDEZ, L MOREIRA, NYSSEN, F MEGRAUD, MORAIN and GISBERT. IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG). In \textit{31st United European Gastroenterology Week 2023}. 2023. ISSN~2050-6406.

Detailed Information on Publication Record